BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 33422803)

  • 1. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
    Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
    Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.
    Khakoo S; Georgiou A; Gerlinger M; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2018 Feb; 122():72-82. PubMed ID: 29458792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer.
    Narayan RR; Goldman DA; Gonen M; Reichel J; Huberman KH; Raj S; Viale A; Kemeny NE; Allen PJ; Balachandran VP; D'Angelica MI; DeMatteo RP; Drebin JA; Jarnagin WR; Kingham TP
    Ann Surg Oncol; 2019 Jun; 26(6):1824-1832. PubMed ID: 30706231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
    Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis.
    Wullaert L; van Rees JM; Martens JWM; Verheul HMW; Grünhagen DJ; Wilting SM; Verhoef C
    Cells; 2023 Oct; 12(21):. PubMed ID: 37947598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.
    Zheng J; Qin C; Wang Q; Tian D; Chen Z
    EBioMedicine; 2024 May; 103():105109. PubMed ID: 38614009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
    Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
    Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
    Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
    Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study.
    Li Y; Xu J; Hu X; Chen Y; Liu F; Chen Y; Ma X; Dong Q; Sun L; Mo S; Zhang L; He X; Tong S; Wu H; Li W; Cai S; Zhu S; Pan Q; Peng J
    Int J Surg; 2024 May; 110(5):2776-2787. PubMed ID: 38445460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer.
    Adams AM; Vreeland TJ; Newhook TE
    J Gastrointest Cancer; 2023 Dec; 54(4):1071-1081. PubMed ID: 36562938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases.
    Liu M; Bao Q; Zhao T; Huang L; Zhang D; Wang Y; Yan X; Wang H; Jin K; Liu W; Wang K; Xing B
    Hepatol Int; 2024 Jun; 18(3):1029-1039. PubMed ID: 38427145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.